A Study of SAR428926 in Patients With Advanced Solid Tumors
NCT02575781
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm Malignant
Interventions
DRUG:
SAR428926
Sponsor
Sanofi